Efficacy and safety of an oral, selective TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis: A Phase II, randomized, placebo-controlled trial

Authors
Category Primary study
JournalJournal of Clinical and Aesthetic Dermatology
Year 2019
This article has no abstract
Epistemonikos ID: 8c7bec8229329d1a326d7594580558e3eebeec5e
First added on: Feb 11, 2025